Top Markets
Coin of the day
Gan & Lee Pharmaceuticals. Gan & Lee Pharmaceuticals.

Gan & Lee Pharmaceuticals.

603087
Rang in Aktien #3183
Gan & Lee Pharmaceuticals is a biopharmaceutical enterprise primarily focused... Gan & Lee Pharmaceuticals is a biopharmaceutical enterprise primarily focused on the discovery, development, manufacturing, and marketing of insulin analogues within the Chinese market. Their diverse product portfolio encompasses injectable therapies such as Basalin (an insulin glargine), Prandilin (an insulin lispro), Prandilin 25 (another insulin lispro variant), Raplin (an insulin aspart), Raplin 30 (an insulin aspart 30 formulation), and Similin 30 (an insulin injection). Beyond diabetes treatments, the company also offers various medical devices. Established in 1998, Gan & Lee Pharmaceuticals maintains its corporate headquarters in Beijing, People's Republic of China. The organization underwent a name change in April 2005, transitioning from its former identity as Beijing Gan & Lee Biotechnology Co., Ltd.
Aktienkurs
$9.97
Zuletzt synchronisiert: 2026-08-25
Marktkapitalisierung
$5.96B
Veränderung (1 Tag)
5.06%
Veränderung (1 Jahr)
0.53%
Land
CN
Handel Gan & Lee Pharmaceuticals. (603087)

Kategorie

Kursverlauf für Gan & Lee Pharmaceuticals. (603087)
Höchster Schlusskurs: $10.41 am 2026-08-01

Niedrigster Schlusskurs: $9.67 am 2020-06-01
Kursverlauf der Aktie von Gan & Lee Pharmaceuticals. von 2020 bis 2026
Jährliche Kursentwicklung
Jahr Leistung
2026 (TTM) 0.59%
2025 49.04%
2024 -17.59%
2023 56.66%
2022 -56.78%
2021 -39.34%
2020 0.00%
Aktienkurs vergleichbarer Unternehmen oder Wettbewerber
Unternehmen Aktienkurs Veränderung 1J% Land
$371.13 -21.75%
US
$188.78 -39.02%
FR
$160.53 22.90%
JP
$189.94 24.49%
US
$76.37 -5.96%
CH